论文部分内容阅读
本文以肝细胞生长素（ＨＧＦ）或联合综合治疗，治疗３１例慢性肝炎患者（治疗组），并与同期非ＨＧＦ综合治疗的４１例慢性肝炎患者（对照组）对照。结果：治疗组近期病死率（１６．１％）明显低于对照组（３９％），Ｐ＜０．０５；其黄疸、恶心呕吐等症状的缓解，血清丙氨酸转移酶（ＡＬＴ）速率的降低及血清甲胎蛋白的增加等方面均优于对照组。两组远期复发率无明显差别，但治疗组慢性活动型肝炎的病情活动频度低于对照组。认为ＨＧＦ具有类似人胎儿肝悬滴液治疗的近期疗效，并在稳定肝功能，减少远期肝病活动等方面有较好效果。
In this paper, 31 patients with chronic hepatitis (treatment group) were treated with hepatocyte growth-promoting factor (HGF) or combination therapy, and were compared with 41 patients with chronic hepatitis (non-HGF) treated by the same period. Results: The recent mortality of the treatment group (16.1%) was significantly lower than that of the control group (39%) (P <0.05). The clinical symptoms of jaundice, nausea and vomiting were relieved. The serum ALT Reduce and increase serum alpha-fetoprotein and other aspects are better than the control group. There was no significant difference in long-term recurrence between the two groups, but the activity frequency of chronic active hepatitis in the treatment group was lower than that in the control group. It is concluded that HGF has similar efficacy in the treatment of human fetal liver drip solution and has good effect in stabilizing liver function and reducing long-term liver disease activity.